STAAR Surgical (STAA)
(Delayed Data from NSDQ)
$31.60 USD
+0.21 (0.67%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $31.61 +0.01 (0.03%) 4:52 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.60 USD
+0.21 (0.67%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $31.61 +0.01 (0.03%) 4:52 PM ET
2-Buy of 5 2
C Value D Growth A Momentum D VGM
Zacks News
Staar Surgical (STAA) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Implied Volatility Surging for STAAR Surgical (STAA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to STAAR Surgical (STAA) stock based on the movements in the options market lately.
Why Staar Surgical (STAA) International Revenue Trends Deserve Your Attention
by Zacks Equity Research
Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Staar Surgical (STAA) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 32% and 4.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Becton Dickinson (BDX) Q3 Earnings Beat Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 5.74% and 1.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Don't Overlook Staar Surgical (STAA) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Wall Street's Insights Into Key Metrics Ahead of Staar Surgical (STAA) Q1 Earnings
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Staar Surgical (STAA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Dentsply International (XRAY) Meets Q1 Earnings Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 0% and 1.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
by Zacks Equity Research
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in West Pharmaceutical (WST): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
West Pharmaceutical (WST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Staar Surgical (STAA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Staar Surgical (STAA) Beats Q4 Earnings Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 26.32% and 0.30%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Key Metrics Tell Us About Staar Surgical (STAA) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Staar Surgical (STAA) Q2 Earnings Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 25% and 0.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 8.21% and 0.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 8% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 63.64% and 10.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 16.36% and 5.97%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Staar Surgical (STAA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Staar Surgical (STAA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Staar Surgical (STAA) closed at $62.99 in the latest trading session, marking a +0.24% move from the prior day.